BACKGROUND: Although pathways associated with hemostasis and thrombosis are well documented to have an impact on venous thromboembolism (VTE), whether the inflammatory cascade also influences VTE risk is uncertain. METHODS AND RESULTS: We evaluated 51 polymorphisms from 32 inflammation-related genes (and an additional 19 polymorphisms from 15 thrombosis-related genes) as potential determinants of VTE in a prospective cohort of 22 413 white women followed over a 10-year period. Hazard ratios (HRs) for incident VTE according to the different genotypes were assessed by Cox proportional-hazards models. The false discovery rate (FDR) was used for correction for multiple testing with a 0.20 cut point. During follow-up, 158 idiopathic and 180 secondary VTE events occurred. As anticipated, factor V Leiden (HR, 3.22; 95% CI, 1.92 to 5.40; P<0.0001; FDR=0.004) and the prothrombin mutation (HR, 2.57; 95% CI, 1.64 to 4.02; P<0.0001; FDR=0.004) were both strongly associated with incident idiopathic VTE, as was the rs6046 polymorphism in the factor VII gene (HR, 0.54; 95% CI, 0.35 to 0.86; P=0.008; FDR, 0.12). With regard to polymorphism in the inflammatory genes, variation at rs1143634 in the IL-1beta gene was associated with a reduced risk of idiopathic VTE (HR, 0.59; 95% CI, 0.44 to 0.80; P=0.0007; FDR=0.02), whereas variation at rs1800872 in the IL-10 gene was associated with increased risk (HR, 1.42; 95% CI, 1.12 to 1.80; P=0.004; FDR=0.07). By contrast, no significant associations were found for secondary VTE events. CONCLUSIONS: In addition to previously reported polymorphisms associated with hemostasis and thrombosis, these prospective cohort data suggest that genetic variation in IL-1 beta and IL-10 genes may also influence the risk of idiopathic VTE.
BACKGROUND: Although pathways associated with hemostasis and thrombosis are well documented to have an impact on venous thromboembolism (VTE), whether the inflammatory cascade also influences VTE risk is uncertain. METHODS AND RESULTS: We evaluated 51 polymorphisms from 32 inflammation-related genes (and an additional 19 polymorphisms from 15 thrombosis-related genes) as potential determinants of VTE in a prospective cohort of 22 413 white women followed over a 10-year period. Hazard ratios (HRs) for incident VTE according to the different genotypes were assessed by Cox proportional-hazards models. The false discovery rate (FDR) was used for correction for multiple testing with a 0.20 cut point. During follow-up, 158 idiopathic and 180 secondary VTE events occurred. As anticipated, factor V Leiden (HR, 3.22; 95% CI, 1.92 to 5.40; P<0.0001; FDR=0.004) and the prothrombin mutation (HR, 2.57; 95% CI, 1.64 to 4.02; P<0.0001; FDR=0.004) were both strongly associated with incident idiopathic VTE, as was the rs6046 polymorphism in the factor VII gene (HR, 0.54; 95% CI, 0.35 to 0.86; P=0.008; FDR, 0.12). With regard to polymorphism in the inflammatory genes, variation at rs1143634 in the IL-1beta gene was associated with a reduced risk of idiopathic VTE (HR, 0.59; 95% CI, 0.44 to 0.80; P=0.0007; FDR=0.02), whereas variation at rs1800872 in the IL-10 gene was associated with increased risk (HR, 1.42; 95% CI, 1.12 to 1.80; P=0.004; FDR=0.07). By contrast, no significant associations were found for secondary VTE events. CONCLUSIONS: In addition to previously reported polymorphisms associated with hemostasis and thrombosis, these prospective cohort data suggest that genetic variation in IL-1 beta and IL-10 genes may also influence the risk of idiopathic VTE.
Authors: A Gerhardt; R E Scharf; M W Beckmann; S Struve; H G Bender; M Pillny; W Sandmann; R B Zotz Journal: N Engl J Med Date: 2000-02-10 Impact factor: 91.245
Authors: S A Burstein; J Peng; P Friese; R F Wolf; P Harrison; T Downs; K Hamilton; P Comp; G L Dale Journal: Stem Cells Date: 1996 Impact factor: 6.277
Authors: D Tormene; V De Stefano; E Grandone; T Za; M Perlati; E Rossi; M Margaglione; P Simioni Journal: J Thromb Haemost Date: 2007-11 Impact factor: 5.824
Authors: Irene D Bezemer; Lance A Bare; Carine J M Doggen; Andre R Arellano; Carmen Tong; Charles M Rowland; Joseph Catanese; Bradford A Young; Pieter H Reitsma; James J Devlin; Frits R Rosendaal Journal: JAMA Date: 2008-03-19 Impact factor: 56.272
Authors: Nicholas L Smith; Lucia A Hindorff; Susan R Heckbert; Rozenn N Lemaitre; Kristin D Marciante; Kenneth Rice; Thomas Lumley; Joshua C Bis; Kerri L Wiggins; Frits R Rosendaal; Bruce M Psaty Journal: JAMA Date: 2007-02-07 Impact factor: 56.272
Authors: I Martinelli; T Battaglioli; V De Stefano; D Tormene; L Valdrè; E Grandone; A Tosetto; P M Mannucci Journal: J Thromb Haemost Date: 2007-12-19 Impact factor: 5.824
Authors: Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom Journal: Am J Med Date: 2002-12-01 Impact factor: 4.965
Authors: Bryce Buchowicz; Tiffany Yu; Dwight M Nance; Frank P Zaldivar; Dan M Cooper; Gregory R Adams Journal: Pediatr Res Date: 2010-11 Impact factor: 3.756
Authors: N A Zakai; L Lange; W T Longstreth; E S O'Meara; J L Kelley; M Fornage; D Nikerson; M Cushman; A P Reiner Journal: J Thromb Haemost Date: 2011-02 Impact factor: 5.824
Authors: Robert C Barber; Nicole R Phillips; Jeffrey L Tilson; Ryan M Huebinger; Shantanu J Shewale; Jessica L Koenig; Jeffrey S Mitchel; Sid E O'Bryant; Stephen C Waring; Ramon Diaz-Arrastia; Scott Chasse; Kirk C Wilhelmsen Journal: PLoS One Date: 2015-12-01 Impact factor: 3.240
Authors: Wei-Dong Li; Hongxiao Jiao; Kai Wang; Clarence K Zhang; Joseph T Glessner; Struan F A Grant; Hongyu Zhao; Hakon Hakonarson; R Arlen Price Journal: Obesity (Silver Spring) Date: 2013-05-24 Impact factor: 5.002